Where biopharma science meets manufacturing reality.
Better Biopharma follows biopharma experts, scientists, editors, and consultants through the practical work behind modern medicines. Its strongest conversations connect molecule design, facility planning, regulatory risk, manufacturing cost, and clinical promise without treating any one piece as separate from execution.
PRESS PLAY
Better Biopharma is a practical interview series about what it takes to make complex medicines real. Its center of gravity is not hype around a new modality, but the chain of decisions that determines whether a therapy can be developed, manufactured, validated, scaled, and delivered. The show often begins with advanced science. Multispecific antibodies, secretomes, regulatory T-cell reprogramming, regenerative skin therapies, and bacterial vector-based immunotherapies all appear in the recent run. Then the conversation turns toward constraints. Format selection can affect manufacturability. Facility plans can decide whether a site adapts or stalls. Autologous products can make every patient its own manufacturing lot. AI tools can look useful on paper while raising unresolved questions about data governance, validation, and GMP expectations. That movement from mechanism to execution gives the show its value. It respects the biology, but it does not stop at the biology. The best moments arrive when a guest explains how a scientific idea changes the work of release testing, process control, quality assurance, documentation, or scale-up. Episodes about master planning and automation are especially operational, with attention to legacy footprints, single-use systems, MES rollouts, pressure cascades, and the danger of postponing facility decisions until failure forces them. Episodes on cell and regenerative medicine balance therapeutic ambition with manufacturing math, including turnaround time, personnel needs, quality control, and the difficulty of maintaining potency through manipulation. The regulatory conversations are similarly grounded. AI is discussed less as a novelty than as a tool that must be de-risked, documented, and matched to the right use cases. Tyler Minichiello’s interview style is steady and contextual. Questions usually frame the problem, narrow the technical issue, and invite the guest to connect details back to patient impact or industry practice. The tone is serious, curious, and work-focused. Better Biopharma suits listeners who want the machinery behind modern biopharma, not only the headline science. It is especially strong for people who think clinical promise and manufacturability should be discussed in the same room.
Made for: Built for biopharma professionals, life sciences editors, consultants, and scientifically fluent listeners who want practical context around biopharma development. It assumes comfort with industry language but rewards attention with clear operational stakes.
What sets it apart: The show connects therapeutic mechanisms to the less glamorous decisions that determine whether products survive development: design choices, facility constraints, validation, release testing, automation, quality systems, and cost. It gives technical guests room to explain their work while keeping the discussion tied to patient access and production reality.
“How can biopharma improve?” This question is the guiding ethos of the Better Biopharma podcast. Through conversations with experts across the biopharma landscape, host Tyler Menichiello explores the work being done to make better medicines and optimize manufacturing. Each episode is a dive into the guest's methods, their curiosity, and their determination. By shining a light on the visionaries pushing the industry forward, Better Biopharma aims to inform and inspire their peers to continue doing the same.
Tyler Menichello makes the factory floor where your biotech optimism meets validation paperwork.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A grounded look at turning a cell-free secretome into a controlled, testable biologic.
ST-266 comes across as a secretome, essentially a cell therapy without the cells, with Dr. Larry Brown framing it through the manufacturing decisions that make the idea plausible.
A measured editorial roundtable connects short-form media, infectious-disease response, and the practical work of covering biopharma.
Better Biopharma's mid-year roundtable brings Tyler Minichiello together with colleagues from Pharmaceutical Online, Outsource Pharma, LifeScience Leader, Drug Discovery Online, Clinical Supply Leader, and Cell and Gene for a broad check-in across the LifeScience Connect…
A cell-therapy conversation that keeps autoimmune mechanism and manufacturing economics in the same room.
Better Biopharma keeps its premise clear: if regulatory T-cells can preserve immune tolerance, they may also be reprogrammed to target the same antigens while reducing autoimmune damage. Dr.
Clinical research, reduced to its practical signal.
Critical care evidence, carefully talked through.
Oncology evidence translated into clinical decisions.
Evidence translated into clinical next steps.
Better Biopharma host Tyler Manichello interviews Larry Brown, Chief Scientific Officer at Novion Biotherapeutics, about ST-266, a cell-free secretome made from placenta-derived amnion epithelial cells.
Better Biopharma host Tyler Minichiello leads a midyear 2026 roundtable with editors from Pharmaceutical Online, Outsource Pharma, Life Science Leader, Drug Discovery Online, Clinical Supply Leader, Cell and Gene, Clinical Leader, and Advancing RNA.
Dr.
Dr.
Interius BioTherapeutics' Sianny Christanti and Babu Medi discuss their in vivo CAR-T therapy INT2104 for B-cell malignancies, aiming to eliminate complex ex vivo manufacturing.